Minerva Neurosciences | NERV - Stammkapital





Stammkapital Veränderung Datum
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Adma Biologics USD 237.88M 457K 2025-12
ALKERMES USD 166.46M 855K 2026-03
Alterity Therapeutics Limited AUD 10.88B 10.66B 2025-12
AstraZeneca USD 1.55B 73K 2026-03
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cipla INR 807.78M 17K 2026-03
Clal Biotechnology ILS 1.61M 0 2022-12
Compugen USD 94.55M 1.02M 2025-12
CSL USD 482.13M 93.87M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Esperion Therapeutics USD 245.22M 39.79M 2025-12
GlaxoSmithKline GBP 4.05B 20.6M 2026-03
Grifols EUR 680.58M 846.11K 2025-12
Halozyme Therapeutics USD 118.52M 741K 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
J&J USD 2.41B 1.74M 2025-12
Merck USD 2.47B 12.72M 2025-12
Minerva Neurosciences USD 1000 0 2024-09
Neurocrine Biosciences USD 100.6M 500K 2026-03
Novartis USD 1.91B 60K 2026-03
Novavax USD 162.58M 106K 2025-12
Pfizer USD 5.7B 13M 2026-03
Roche Holding CHF 795.62M 699.54K 2025-12
Sanofi EUR 1.21B 8.25M 2026-03
Takeda JPY 1.58B 241K 2026-03
Vanda Pharmaceuticals USD 58K 0 2024-12